Castellan Group’s Pfizer PFE Stock Holding History

Castellan Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-57,400	Closed	-$2.47M	–	84
2021 Q3	$2.47M	Sell	57,400 -150,500	-72%	-$6.67M	1.27%	13
2021 Q2	$8.14M	Hold	207,900	–	–	3.41%	7
2021 Q1	$7.53M	Buy	+207,900	New	+$7.38M	4.02%	7

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Castellan Group's PFE Position: Q4 2021 in Review

Castellan Group sold out of Pfizer (PFE) in Q4 2021, closing a stake of 57,400 shares — an estimated $2.47M sold.

Castellan Group first reported a position in PFE in Q1 2021 and held it in 3 quarters. The position peaked at $8.14M in Q2 2021. 3,262 funds tracked by Wall St. Rank hold PFE as of Q4 2021.

Castellan Group reported no remaining Pfizer position as of Q4 2021 after selling out during the quarter.
Castellan Group sold 57,400 Pfizer shares in Q4 2021, an estimated $2.47M.
Castellan Group first reported a position in Pfizer in Q1 2021 and held it in 3 quarters.
Castellan Group's Pfizer position peaked at $8.14M in Q2 2021.
3,262 funds tracked by Wall St. Rank held Pfizer as of Q4 2021.

Based on Castellan Group's 13F filing for Q4 2021, filed 16 Feb 2022.